Aker BioMarine Plans US NDI Notification For EPA/DHA Formulated To Pass Blood-Brain Barrier
Executive Summary
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.